STOCK TITAN

ParkerVision permits resale of up to 16.8M shares

ParkerVision would receive no proceeds from resales, while cash exercises of two warrants could yield up to $3,900,000 gross.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
424B3

Rhea-AI Filing Summary

ParkerVision’s prospectus permits selling stockholders to resell up to 16,809,295 shares of common stock. The shares include up to 4,961,538 issuable upon conversion of convertible notes and for interest payments at ParkerVision’s option; 3,907,331 issued under securities purchase agreements; 2,740,426 issued for services and repayment of short-term loans and other payables; and warrant shares: up to 5,000,000 at $0.74 per share and up to 200,000 at $1.00 per share.

ParkerVision receives no proceeds from resales. Cash exercise of the Aspire and Tailwinds warrants could generate up to $3,900,000 in gross proceeds, which ParkerVision expects to use for general working capital and corporate purposes. Separately, ParkerVision disclosed that the Court of Appeals for the Federal Circuit issued an order on October 1, 2026, in the expedited appeal of its patent infringement case against Qualcomm.

Filing Explained

This Form 424B3 updates earlier registration statements to maintain their effectiveness; ParkerVision says the update itself involves no new securities issuance, so this filing does not itself issue shares.

Shares permitted for resale up to 16,809,295 shares ParkerVision common stock
Shares issuable under notes up to 4,961,538 shares Conversion and interest payments at ParkerVision’s option
Shares issued under securities purchase agreements 3,907,331 shares Agreements dated January 9, 2020, January 15, 2020, March 5, 2020, and March 19, 2020
Shares issued for services and repayment 2,740,426 shares Services, short-term loans, and other accounts payable, including interest
Aspire warrant shares up to 5,000,000 shares Five-year warrant; exercise price of $0.74 per share
Tailwinds warrant shares up to 200,000 shares Three-year warrant; exercise price of $1.00 per share
Gross proceeds from warrant exercises up to $3,900,000 If the Aspire and Tailwinds warrants are exercised for cash
Note conversion prices $0.10 per share and $0.13 per share September 13, 2019 note and January 8, 2020 notes, respectively
convertible promissory note financial
"a convertible promissory note dated September 13, 2019"
A convertible promissory note is a loan a company takes now that can later be turned into shares instead of being repaid in cash. Think of it as lending money with the option to accept ownership in the business down the road; that matters to investors because it affects who gets paid first, how much ownership existing shareholders keep, and the company’s future valuation and cash needs. Terms such as conversion price, interest and maturity determine the financial impact.
fixed conversion price financial
"which has a fixed conversion price of $0.10 per share"
exercise price financial
"with an exercise price of $0.74 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
gross proceeds financial
"up to an aggregate of $3,900,000 in gross proceeds"
The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.
Offering Type secondary
Securities Offered Common Stock
Offering Amount 16,809,295 shares
Use of Proceeds ParkerVision receives no proceeds from selling stockholders’ resales. If the Aspire and Tailwinds warrants are exercised for cash, ParkerVision may receive up to $3,900,000 in gross proceeds, which it expects to use for general working capital and corporate purposes.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PRKR shares can selling stockholders resell?

Selling stockholders may resell up to 16,809,295 shares of ParkerVision common stock. The shares include stock issued or issuable through convertible notes, securities purchase agreements, services and loan or payable settlements, and two warrant agreements.

Does ParkerVision receive proceeds from PRKR share sales?

ParkerVision receives no proceeds from selling stockholders’ resales. If the Aspire and Tailwinds warrants are exercised for cash, ParkerVision could receive up to $3,900,000 in gross proceeds, which it expects to use for general working capital and corporate purposes.

What are the conversion prices for ParkerVision’s notes?

The September 13, 2019 note has a fixed conversion price of $0.10 per share, and the January 8, 2020 notes have a fixed conversion price of $0.13 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

Filed pursuant to Rule 424(b)(3)

Registration No. 333-237762

 

PROSPECTUS SUPPLEMENT No. 78

(to Prospectus dated April 28, 2020)

 

PARKERVISION, INC.

16,809,295 Shares of Common Stock

 

This Prospectus Supplement relates to the prospectus dated April 28, 2020, as amended and supplemented from time to time (the “Prospectus”), which permits the resale by the selling stockholders listed in the Prospectus of up to 16,809,295 shares of our common stock, par value $0.01 per share (“Common Stock”) consisting of (i) up to 4,961,538 shares of Common Stock issuable upon conversion of, and for the payment of interest from time to time at our option, for a convertible promissory note dated September 13, 2019 which has a fixed conversion price of $0.10 per share and convertible promissory notes dated January 8, 2020 which have a fixed conversion price of $0.13 per share (the “Notes”), (ii) an aggregate of 3,907,331 shares of Common Stock issued pursuant to securities purchase agreements dated January 9, 2020, January 15, 2020, March 5, 2020 and March 19, 2020, (iii) an aggregate of 2,740,426 shares of Common Stock issued as payment for services and repayment of short-term loans and other accounts payable, including interest, (iv) up to 5,000,000 shares of Common Stock issuable upon exercise of a five-year warrant with an exercise price of $0.74 per share, subject to adjustment and issued pursuant to a warrant agreement with Aspire Capital Fund LLC (“Aspire”) and (v) up to 200,000 shares of Common stock issuable upon exercise of a three-year warrant with an exercise price of $1.00 per share, subject to adjustment and issued pursuant to a warrant agreement with Tailwinds Research Group LLC (“Tailwinds”).

 

We will not receive proceeds from the sale of the shares of Common Stock by the selling stockholders. To the extent the Aspire and Tailwinds warrants are exercised for cash, we will receive up to an aggregate of $3,900,000 in gross proceeds. We expect to use proceeds received from the exercise of the Aspire and Tailwinds warrants, if any, for general working capital and corporate purposes.

 

This Prospectus Supplement is being filed to update and supplement the information previously included in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on October 1, 2026.  Accordingly, we have attached the 8-K to this prospectus supplement.  You should read this prospectus supplement together with the prospectus, which is to be delivered with this prospectus supplement.

 

Any statement contained in the Prospectus shall be deemed to be modified or superseded to the extent that information in this Prospectus Supplement modifies or supersedes such statement.  Any statement that is modified or superseded shall not be deemed to constitute a part of the Prospectus except as modified or superseded by this Prospectus Supplement.

 

This Prospectus Supplement should be read in conjunction with, and may not be delivered or utilized without, the Prospectus.

 

Our Common Stock is listed on the OTCQB Venture Capital Market under the ticker symbol “PRKR.” 

 

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 6 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.

 

Neither the SEC nor any such authority has approved or disapproved these securities or determined whether this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this Prospectus Supplement is October 1, 2026.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 1, 2026

 

PARKERVISION, INC.

(Exact Name of Registrant as Specified in Charter)

     

Florida

000-22904

59-2971472

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

   

4446-1A Hendricks Avenue Suite 354, Jacksonville, Florida

32207

(Address of Principal Executive Offices)

(Zip Code)

 

(904) 732-6100

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

None

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

 

Emerging growth company   ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 

 

Item 8.01 Other Events

 

On October 1, 2026,  ParkerVision, Inc. (the “Company”) issued a press release announcing that the Court of Appeals for the Federal Circuit issued its order in the expedited appeal of the Company's patent infringement case against Qualcomm.  A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

 

The information contained in this Current Report on Form 8-K, including Exhibit 99.1 hereto, has been “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section. The information in this Current Report shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

 

The Company will file prospectus supplements on Form 424B3 to update previously filed S-1 registration statements to maintain their effectiveness.  These Form 424B3 filings typically follow the filing of the Company's periodic reports with the SEC, including Forms 8-K, and do not involve the issuance of any new securities by the Company.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit Description
99.1 Press Release
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     

Dated: October 1, 2026

   
   

PARKERVISION, INC.

     
   

By /s/ Cynthia French

   

Cynthia French

   

Chief Financial Officer

 

 

Keep reading